RCUS•benzinga•
Arcus Biosciences Announces Gilead's Time-Limited Exclusive Option Rights To Casdatifan Have Expired; Co. Prices $150M Common Stock Offering Enabling Arcus To Independently Advance Its Development Program For Casdatifan
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 18, 2025 by benzinga